annb0t
Top 20
Immutep Limited (NASDAQ: IMMP) announced new interim data from 2nd line non-small cell lung cancer (NSCLC) patients (Part B) in the Phase 2 TACTI-002 trial. Part B evaluates Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in 36 patients. Median overall survival (OS) was 9.7 months for those who received chemo-free therapy of efti in combination with pembrolizumab, comparable with the current standa...
>>> Read more: Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment
>>> Read more: Immutep's Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment
